Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10151 - 10175 of 12422 in total
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Matched Description: … It is a member of a new family of pharmaceutical compounds called vomeropherins. ... PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized …
BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Investigational
APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.
Investigational
Matched Description: … APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet …
Captodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine. Captodiame has been suggested for use in preventing benzodiazepine withdrawal syndrome.
Experimental
Matched Description: … It is a derivative of diphenhydramine. …
Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa...
Investigational
Matched Description: … Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of ... It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions ... of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions …
Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak Pharmaceuticals. A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared...
Investigational
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Description: … treatment of various immuno-inflammatory conditions. ... Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the ... While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are …
Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Investigational
Investigational
Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411...
Investigational
Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet...
Investigational
Matched Description: … In a 2004 issue of Science, Dr. ... It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene ... Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. …
Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).
Investigational
Matched Description: … Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome). ... Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple …
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … ), an end product of the leukotriene pathway and a potent promoter of inflammation. ... of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. ... DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4 …
An inhibitor of members of the Bcl‑2 family of apoptosis regulators.
Investigational
Matched Description: … An inhibitor of members of the Bcl‑2 family of apoptosis regulators.[A252977] …
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large...
Investigational
Matched Description: … As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and ... Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological ... Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation …
Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in...
Experimental
Matched Description: … , blockage of its effects results in a decreases in systemic vascular resistance. ... As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone …
ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the...
Investigational
Matched Description: … ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable ... ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food ... and Drug Administration in the United States for consideration for the treatment of stroke in humans …
Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). Tideglusib is being developed by the Spanish pharmaceutic company Zeltia...
Investigational
Withdrawn
Matched Description: … Alzheimer's disease as of 2012. ... Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for ... reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers. ... Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell ... XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated …
KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.
Investigational
Matched Description: … KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of
AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that...
Investigational
Matched Description: … against COVID-19 - a significantly longer window of efficacy than that of other vaccines. ... [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection ... trials for the prevention and treatment of COVID-19. …
PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection and other sexually transmitted diseases. This medicine does not cure HIV infection or AIDS and is being studied to reduce...
Investigational
Matched Description: … PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical ... It is being studied for the prevention of HIV infection and other sexually transmitted diseases. ... This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing …
Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity).
Investigational
Matched Description: … (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity ... Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 …
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Matched Description: … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic ... pathway of the blood coagulation system. ... as an anticoagulant for the treatment of thromboembolic disorders. …
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Displaying drugs 10151 - 10175 of 12422 in total